---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030276"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:59:58.773481+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart initiates sentinel cohort of Phase 2b oral COVID-19 vaccine trial; BARDA raises funding to $456M

## Summary
- Modification No. 3 increased total estimated ceiling to ~$456.1M (+$3.2M) and allotted funding to ~$96.5M (+$30.8M).
- Sentinel cohort of 400 participants (200 Vaxart oral pill, 200 mRNA comparator) begins; 30-day safety data will trigger enrollment of 10,000.
- Trial will measure efficacy against symptomatic/asymptomatic disease, systemic and mucosal immunity, and safety.
- Funding via Project NextGen (BARDA); full Phase 2b primary efficacy analysis at 12 months post-vaccination.
- Vaxart's XBB vaccine construct and newly funded KP.2-targeting construct are part of the study.

## SEC filing metadata
- accession: 0001437749-24-030276
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774924030276/0001437749-24-030276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774924030276/vxrt20240930_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030276
- JSON: https://secwatch.observer/filing/0001437749-24-030276.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.